PIRS (Pieris Pharmaceuticals) Multiplikator Forward P/S

Lambang korporat lan logo Pieris Pharmaceuticals (PIRS)

Risks are associated with crisis management and the struggle for capital survival for Pieris Pharmaceuticals (PIRS). This chart on the GURU.Markets platform illustrates the expected revenue multiple, where the 821.20 metric determines the status of the support parameter. Stability is based on protein test outcomes, while growth potential relies on the development of the Anticalin platform and new partnerships with biotech firms.

Pieris Pharmaceuticals, Inc. - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep PIRS (periode 04.07.2022 - 31.12.2025)

Rincian analitis perusahaan Pieris Pharmaceuticals

- rega pasar lan target rega analis:
Bagan rega Pieris Pharmaceuticals, Inc.|PIRS - Bagan tingkat prakiraan
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Pieris Pharma|PIRS - Rega Tumbas Perusahaan
- statistik nilai buku emiten:
Nilai Buku saben Saham Pieris Pharmaceuticals|PIRS - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku pieris.com|PIRS - Nilai Agregat Aset
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Pieris Pharmaceuticals|PIRS - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Pieris Pharmaceuticals|PIRS - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Pieris Pharma|PIRS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pieris Pharmaceuticals|Rasio cepet pieris.com
- rincian asil keuangan lan kelipatan valuasi:
PIRS - Bathi pungkasan|Proyeksi bathi mangsa ngarep Pieris Pharmaceuticals|PIRS - Pangali P/E|Rega marang bathi mangsa ngarep Pieris|PIRS - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Pieris Pharma|PIRS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Pieris Pharmaceuticals|PIRS - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan pieris.com|PIRS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Pieris Pharmaceuticals
- rincian pendapatan lan dodolan:
PIRS - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Pieris Pharmaceuticals, Inc.|PIRS - Multiplikator P/S|Multiplikator forward rega marang pendapatan Pieris Pharma
Analisis komprehensif perusahaan:Pieris Pharmaceuticals, Inc. (PIRS)
Sampel barang Pieris Pharmaceuticals

The forward P/S ratio compares current market capitalization with projected sales volume, allowing for an assessment of market expectations regarding revenue growth rates prior to the release of official financial reports. An analysis of the forward P/S history reveals the operational resilience of Pieris Pharmaceuticals (PIRS), demonstrating how investors value the commercialization potential of Anticalin proteins within the context of an academic approach to drug development.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Jyong Bio MENS|LGND: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep amneal.com (AMRX)|Rasio rega marang prakiraan pendapatan Perrigo|ALVO: Rega forward marang dodolan|Multiplikator Forward P/S LQDA|Rasio kapitalisasi marang dodolan sing dikarepake Galapagos Corp|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|Rasio kapitalisasi marang dodolan sing dikarepake mannkindcorp.com (MNKD)|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TBPH (Theravance Corp)|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Multiplikator Forward P/S Tonix Pharma (TNXP)|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|invizyne.com (EXOZ) - Multiplikator forward rega marang pendapatan|ORMP: Multiplikator Forward P/S|Entera Bio (ENTX) - Multiplikator Forward P/S|HYFT (MindWalk) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ABVC BioPharma, Inc (ABVC)|Multiplikator Forward P/S CPIX|QNTM - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|FibroGen - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Telomir Pharmaceuticals Inc TELO|RANI: Multiplikator forward rega marang pendapatan|Synergy CHC Corp - Rasio rega marang pendapatan sing dikarepake|RLYB: Multiplikator Forward P/S|LEXX - Rasio kapitalisasi marang dodolan sing dikarepake|PULM (Pulmatrix) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pheton (PTHL)|Multiplikator Forward P/S APM|Multiplikator Forward P/S Lyra Therapeutics Inc (LYRA)|Rasio rega marang prakiraan pendapatan Impact BioMedical Inc IBO|TNF Pharmaceuticals Inc. - Rasio rega marang prakiraan pendapatan|YCBD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake PainReform Ltd PRFX|altamiratherapeutics.com (CYTO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan LIPO (Lipella Pharma)|OPTN (OptiNose, Inc.) - Multiplikator Forward P/S|procapsgroup.com (PROC) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|Rasio kapitalisasi marang dodolan sing dikarepake TFF Pharmaceuticals, Inc (TFFP)